ICUI Stock Analysis: ICU Medical | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 3.796m USD | 12M Return: 12.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 42.7M
EPS Trend: 47.7%
Qual. Beats: 8
Rev. Trend: -5.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ICU Medical, Inc. (NASDAQ: ICUI) is a San Clemente, California-based medical device company founded in 1984 that develops, manufactures, and sells products used in infusion therapy, vascular access, and vital care applications worldwide. Its portfolio spans needle-free connectors, catheter patency devices, closed system transfer devices for hazardous drugs, IV solutions, infusion pumps, medication safety software, hemodynamic monitoring tools, and anesthesia and respiratory products.
The company sells primarily to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities such as home health care providers and long-term care facilities. As a mid-cap player in the Health Care Supplies sub-industry, ICU Medical operates in a sector characterized by FDA-regulated products and a mix of capital equipment (e.g., infusion pumps) and recurring consumable revenue (e.g., connectors, IV fluids, disinfection caps), which is typical of medical supplies businesses serving hospital and clinical channels.
- IV solution demand surges as Baxter plant remains offline
- Smiths Medical integration continues to pressure gross margins
- Plum 360 pump gains hospital share post BD Alaris recall
| Net Income: 46.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -1.21 > 1.0 |
| NWC/Revenue: 31.12% < 20% (prev 36.15%; Δ -5.03% < -1%) |
| CFO/TA 0.04 > 3% & CFO 167.4m > Net Income 46.3m |
| Net Debt (1.10b) to EBITDA (262.7m): 4.18 < 3 |
| Current Ratio: 2.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (25.2m) vs 12m ago 2.62% < -2% |
| Gross Margin: 36.36% > 18% (prev 35.11%; Δ 1.25% > 0.5%) |
| Asset Turnover: 52.61% > 50% (prev 57.83%; Δ -5.22% > 0%) |
| Interest Coverage Ratio: 0.66 > 6 (EBIT TTM 57.9m / Interest Expense TTM 87.5m) |
| A: 0.17 (Total Current Assets 1.19b - Total Current Liabilities 517.9m) / Total Assets 4.01b |
| B: 0.18 (Retained Earnings 721.0m / Total Assets 4.01b) |
| C: 0.01 (EBIT TTM 57.9m / Avg Total Assets 4.10b) |
| D: 1.11 (Book Value of Equity 2.11b / Total Liabilities 1.90b) |
| Altman-Z'' = 2.94 = A |
| DSRI: 1.10 (Receivables 201.1m/204.7m, Revenue 2.16b/2.42b) |
| GMI: 0.97 (GM 35.11% / 36.36%) |
| AQI: 1.07 (AQ_t 0.58 / AQ_t-1 0.54) |
| SGI: 0.89 (Revenue 2.16b / 2.42b) |
| TATA: -0.03 (NI 46.3m - CFO 167.4m) / TA 4.01b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 154.42 with a total of 196,706 shares traded. Over the past week, the price has changed by -0.35%, over one month by +10.43%, over three months by +22.87% and over the past year by +12.50%.
Current recommended Stop Loss: 147.80 (which is 4.3% or 1.2 ATR below the current price).
ICU Medical has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ICUI.
- StrongBuy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 172.5 | 11.7% |
P/E Trailing = 83.456
P/E Forward = 18.9753
P/S = 1.7602
P/B = 1.834
P/EG = 0.0879
Revenue TTM = 2.16b USD
EBIT TTM = 57.9m USD
EBITDA TTM = 262.7m USD
Long Term Debt = 1.26b USD (from longTermDebt, last quarter)
Short Term Debt = 34.2m USD (from shortTermDebt, last quarter)
Debt = 1.39b USD (from shortLongTermDebtTotal, last quarter) + Leases 45.2m
Net Debt = 1.10b USD (calculated: Debt 1.39b - CCE 288.3m)
Enterprise Value = 4.89b USD (3.80b + Debt 1.39b - CCE 288.3m)
Interest Coverage Ratio = 0.66 (Ebit TTM 57.9m / Interest Expense TTM 87.5m)
EV/FCF = 60.88x (Enterprise Value 4.89b / FCF TTM 80.4m)
FCF Yield = 1.64% (FCF TTM 80.4m / Enterprise Value 4.89b)
FCF Margin = 3.73% (FCF TTM 80.4m / Revenue TTM 2.16b)
Net Margin = 2.15% (Net Income TTM 46.3m / Revenue TTM 2.16b)
Gross Margin = 36.36% ((Revenue TTM 2.16b - Cost of Revenue TTM 1.37b) / Revenue TTM)
Gross Margin QoQ = 32.64% (prev 37.41%)
Tobins Q-Ratio = 1.22 (Enterprise Value 4.89b / Total Assets 4.01b)
Interest Expense / Debt = 6.31% (Interest Expense 87.5m / Debt 1.39b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 45.7m (EBIT 57.9m * (1 - 21.00%))
Current Ratio = 2.30 (Total Current Assets 1.19b / Total Current Liabilities 517.9m)
Debt / Equity = 0.66 (Debt 1.39b / totalStockholderEquity, last quarter 2.11b)
Debt / EBITDA = 4.18 (Net Debt 1.10b / EBITDA 262.7m)
Debt / FCF = 13.66 (Net Debt 1.10b / FCF TTM 80.4m)
Total Stockholder Equity = 2.12b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.13% (Net Income 46.3m / Total Assets 4.01b)
RoE = 2.19% (Net Income TTM 46.3m / Total Stockholder Equity 2.12b)
RoCE = 1.71% (EBIT 57.9m / Capital Employed (Equity 2.12b + L.T.Debt 1.26b))
RoIC = 1.34% (NOPAT 45.7m / Invested Capital 3.42b)
WACC = 7.98% (E(3.80b)/V(5.18b) * Re(9.08%) + D(1.39b)/V(5.18b) * Rd(6.31%) * (1-Tc(0.21)))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 1.90%
[DCF] Terminal Value 73.10% ; FCFF base≈102.0m ; Y1≈89.4m ; Y5≈72.3m
[DCF] Fair Price = 2.46 (EV 1.16b - Net Debt 1.10b = Equity 61.6m / Shares 25.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 47.67 | EPS CAGR: 5.60% | SUE: 1.22 | # QB: 8
Revenue Correlation: -5.93 | Revenue CAGR: -0.21% | SUE: -0.05 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.91 | Chg30d=-0.25% | Revisions=-12% | Analysts=7
EPS next Quarter (2026-09-30): EPS=2.08 | Chg30d=-0.16% | Revisions=-44% | Analysts=7
EPS current Year (2026-12-31): EPS=8.16 | Chg30d=-0.14% | Revisions=+38% | GrowthEPS=+5.1% | GrowthRev=-1.8%
EPS next Year (2027-12-31): EPS=9.30 | Chg30d=-0.31% | Revisions=+38% | GrowthEPS=+14.0% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: +4% (up=11, down=10)